The 8th American Joint Commission of Cancer (AJCC) for breast cancer staging system added genomic assays, HER2, hormone receptors, and histologic grade to the classic TNM staging system, to define the prognostic stage grouping.8 This evidence concerns the gene ERBB2 and breast carcinoma.